Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

AbbVie

Status and phase: Completed; Phase 3

Conditions: Moderate to Severe Plaque Psoriasis

Treatments: Drug: placebo; Biological: ABT-874; Biological: etanercept

Study type: Interventional

Funder types: Industry

Identifiers

NCT00710580

M10-315

Details and patient eligibility

About

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Enrollment: 350 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Psoriasis for 6 MO
• BSA 10%
• PASI 12 or above
• PGA 3 or above

Exclusion criteria

• Previous exposure to either etanercept or ABT-874

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

350 participants in 3 patient groups, including a placebo group

A

Experimental group

Treatment:

Biological: ABT-874

B

Active Comparator group

Treatment:

Biological: etanercept

C

Placebo Comparator group

Treatment:

Drug: placebo